CITIUS ONCOLOGY, INC. Nasdaq Compliance Update: What You Need to Know

If you follow Citius Oncology (ticker: CTOR), you know that spin-offs can be a wild ride. A new development has emerged regarding their Nasdaq listing status that you need to understand. Let’s break it down in plain English.

1. What happened?

Citius Oncology recently received a "deficiency notice" from the Nasdaq. The company failed to meet the rule requiring a minimum share price of $1.00. This happened because the stock closed below $1.00 for 30 consecutive business days.

2. Is the company being kicked off the stock market?

Not yet. This notice is a warning, not an immediate eviction. The company has 180 days—until April 21, 2025—to get back in compliance.

3. How can they fix this?

To regain compliance, the stock must close at $1.00 or higher for at least ten consecutive business days before the April deadline. If they miss this, they may be eligible for a second 180-day extension. To achieve this, companies in this position sometimes perform a "reverse stock split," which combines existing shares to mathematically increase the price per share. The company has not yet announced a specific plan to address this, so we are waiting to see how management chooses to proceed.

4. Why does this matter to you?

Trading under $1.00 often labels a stock as a "penny stock," which introduces specific risks:

• Higher Volatility: Prices may swing wildly as traders speculate on whether the company will recover or be delisted.
• Institutional Barriers: Many large institutional investors, such as pension funds and mutual funds, have mandates that prevent them from holding stocks trading below $1.00.
• Management Focus: Leadership must now balance running the business with the administrative pressure of maintaining their Nasdaq listing.

5. What should you do?

• Don’t Panic: This is a common hurdle for smaller biotech companies. It does not change the company’s daily operations, their cash position, or their ongoing clinical research.
• Watch the Pipeline: Citius focuses on developing cancer treatments. The most sustainable way to push the stock price above $1.00 is through positive business developments. Specifically, watch for updates on Lymphir (denileukin diftitox), their lead treatment for skin lymphoma. Keep an eye out for commercial progress, clinical trial results, or regulatory filings.
• Understand the Risks: If they fail to meet the deadline and any subsequent extensions, the stock could move to "Over-the-Counter" (OTC) markets. Trading on the OTC can make it harder to buy or sell shares and often involves less rigorous reporting requirements than the Nasdaq.

6. The Bottom Line

Citius Oncology is currently in a "prove-it" phase. They have until April 2025 to convince the market that their business is worth more than a dollar a share. As an investor, your focus should remain on their drug development progress and commercial success. That is the real engine that will determine if they stay on the Nasdaq or face a more difficult path ahead.

Decision Checklist:

• Check the Calendar: Mark April 21, 2025, as a key date to monitor for compliance updates.
• Monitor SEC Filings: Keep an eye on the company’s official investor relations page for any announcements regarding a reverse split or other compliance strategies.
• Focus on Fundamentals: Ask yourself if you believe in the long-term potential of Lymphir. If the drug succeeds, the stock price usually follows; if you don't believe in the drug, the listing status is secondary to the underlying business risk.

Disclaimer: I’m explaining the news, not giving financial advice! Always do your own research or talk to a professional before making any trades.